Announced Fri, 14 Aug · 08:42 IST
Gland Pharma appoints Deepak Sapra as new CEO from November 16
GLAND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-2.1%1-day move
₹2965.00
prior close
₹2950.40
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+1.3+1.1+0.9+1.1-2.1-3.7-4.3-3.9-5.2-4.5-0.9———
Up moveDown movePending
AI summary
Gland Pharma's Board has approved the appointment of Mr. Deepak Sapra as the new Chief Executive Officer, effective November 16, 2026, subject to his acceptance. He brings 27 years of experience, with over 23 years in pharma. He currently heads the API and Services business at Dr. Reddy's Laboratories and is also a Board Member at Aurigene Pharma Services. His background covers global generics, CDMO, APIs, business development and M&A across the US, Europe, Japan and emerging markets.
Likely market impact
External hire of a seasoned pharma leader from Dr. Reddy's signals strategic focus on global growth and portfolio expansion.